PFE Earnings Date: Nov 3, 2026 — Pfizer Inc.
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is PFE's next earnings date?
Pfizer Inc. (PFE) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026 at 6:45 AM ET (before market open). The consensus estimate is EPS of $0.73 on revenue of $15.85B.
How did PFE do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Pfizer Inc. posted EPS of $0.77 versus the $0.68 estimate, a beat of 13.2%. Revenue was $15.03B against a $14.43B estimate. The stock's 1-day post-earnings move was +1.5%.
How much does PFE stock move after earnings?
PFE beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.2% (up or down) in the day after earnings.
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
🤖 AI Earnings Analysis
PFE beat EPS estimates by 13.24% and revenue by 4.22%, followed by an 8.07% one-week share-price gain, signaling strong investor response to its earnings.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 0.68 | 0.77 | +13.24% | $15.03B | ✅ Beat | +1.52% | +8.07% | +14.06% |
| 2026-05-05 | Q1 2026 | 0.72 | 0.75 | +4.17% | $14.45B | ✅ Beat | +0.55% | -0.24% | -2.08% |
| 2026-02-03 | Q4 2025 | 0.56 | 0.66 | +17.86% | $17.56B | ✅ Beat | -3.34% | +1.44% | -0.16% |
| 2025-11-04 | Q3 2025 | 0.65 | 0.87 | +33.85% | $16.65B | ✅ Beat | -1.43% | +0.65% | +5.51% |
| 2025-08-05 | Q2 2025 | 0.58 | 0.78 | +34.48% | $14.70B | ✅ Beat | +5.18% | +4.46% | +5.37% |
| 2025-04-29 | Q1 2025 | 0.67 | 0.92 | +37.31% | $13.71B | ✅ Beat | +3.18% | +3.56% | +2.45% |
| 2025-02-04 | Q4 2024 | 0.46 | 0.63 | +36.96% | $17.76B | ✅ Beat | -1.27% | -1.27% | -1.02% |
| 2024-10-29 | Q3 2024 | 0.62 | 1.06 | +70.97% | $17.70B | ✅ Beat | -1.39% | -3.81% | -9.33% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $15.03B total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Biopharma | 97.5% | $14.66B | +2.5% | $17.39B | $17.41B | $14.30B | $16.31B |
| Segment Reporting, Reconciling Item, Corporate Nonsegment | 2.5% | $373.0M | +7.2% | $310.0M | — | $348.0M | $344.0M |
By region
Q2 FY26 · $15.03B total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 58.9% | $8.86B | -0.4% | $12.06B | $9.22B | $8.89B | $10.69B |
| Developed Rest Of World | 24.9% | $3.74B | +10.3% | $3.41B | $6.28B | $3.39B | $3.70B |
| Emerging Markets | 16.2% | $2.43B | +2.9% | $2.23B | $2.26B | $2.37B | $2.27B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.